French company Carmat has secured conditional approval from the US Food and Drug Administration (FDA) to initiate the second ...

Aeson® total artificial heart showing Open view with pumps and electronics (blue), blood chambers (maroon) and conduits (top, white). Image courtesy CARMAT. Disclaimer: AAAS and EurekAlert!

CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a ...

Aeson®: a promising solution for very high-risk patients initially placed on temporary extracorporeal life support Cardiogenic shock is an acute heart failure condition that poses a life ...

The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients with end-stage biventricular heart failure ...

Following a strong start this year, we are determined to progressively establish Aeson® as a reference solution for patients suffering from advanced biventricular heart failure — today in ...

which would enable patients to remain under Aeson® support on a long-term basis. With this objective in mind, we should be in a position to make an enhanced version of our artificial heart ...

During the first quarter of 2025, CARMAT performed 16 Aeson® heart implants in 3 countries (France, Germany, Italy), vs 7 implants in the 1st quarter of 2024. Quarterly sales thus amounted to € ...

which would enable patients to remain under Aeson® support on a long-term basis. With this objective in mind, we should be in a position to make an enhanced version of our artificial heart available ...